Table 2.
Descriptive statistics of each drug cohorts
| Clopidogrel | Warfarin | Citalopram | Escitalopram | Fluoxetine | Fluvoxamine | Paroxetine | Sertraline | Vortioxetine | Combined SSRIs | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cohort size | 2,159 | 1,855 | 3,151 | 2,597 | 2,719 | 117 | 1,100 | 4,052 | 149 | 10,362 |
| Sex at birth, n (%) | ||||||||||
| Male | 1,248 (57.8) | 909 (49.0) | 2,052 (65.1) | 697 (26.8) | 834 (30.7) | 42 (35.9) | 364 (33.1) | 1,332 (32.9) | 37 (24.8) | 4,390 (31.1) |
| Female | 867 (40.2) | 906 (48.8) | 1,040 (33.0) | 1,862 (71.7) | 1,847 (67.9) | 74 (63.3) | 721 (65.6) | 2,668 (65.8) | 110 (73.8) | 9,508 (67.4) |
| Age, mean (SD) | ||||||||||
| At index | 63.1 (10.4) | 60.2 (11.6) | 50.4 (14.3) | 50.2 (15.5) | 48.1 (14.8) | 43.3 (14.2) | 51.6 (13.3) | 49.0 (15.6) | 48.8 (13.4) | 49.4 (15.0) |
| At survey | 66.9 (10.2) | 66.0 (11.6) | 55.9 (15.1) | 52.7 (16.0) | 52.7 (15.8) | 46.4 (15.1) | 57.1 (14.1) | 52.3 (16.3) | 49.6 (13.6) | 53.6 (15.8) |
| Race, n (%) | ||||||||||
| White | 1,571 (72.8) | 1,370 (73.9) | 2,273 (72.1) | 2,003 (77.1) | 1,999 (73.5) | 92 (78.6) | 768 (69.8) | 2,928 (72.3) | 121 (81.2) | 10,341 (73.4) |
| Black or African American | 387 (17.9) | 324 (17.5) | 590 (18.7) | 356 (13.7) | 484 (17.8) | ≤ 20 | 222 (20.2) | 741 (18.3) | ≤ 20 | 2,468 (17.5) |
| Asian | ≤ 20 | ≤ 20 | ≤ 20 | 27 (1.0) | ≤ 20 | 0 (0.0) | ≤ 20 | 36 (0.9) | ≤ 20 | 104 (0.7) |
| Hispanic/Latino, n (%) | 91 (4.2) | 76 (4.1) | 112 (3.6) | 93 (3.6) | 99 (3.6) | ≤ 20 | 51 (4.6) | 175 (4.3) | ≤ 20 | 538 (3.8) |
| Highest education level, n (%) | ||||||||||
| No high school degree | 117 (5.4) | 84 (4.5) | 133 (4.2) | 94 (3.6) | 122 (4.5) | ≤ 20 | 47 (4.3) | 183 (4.5) | ≤ 20 | 593 (4.2) |
| High school graduate | 479 (22.2) | 407 (21.9) | 713 (22.6) | 490 (18.9) | 578 (21.3) | ≤ 20 | 262 (23.8) | 871 (21.5) | 27 (18.1) | 3,018 (21.4) |
| College 1–3 years | 735 (34.0) | 605 (32.6) | 1,057 (33.5) | 827 (31.8) | 899 (33.1) | 38 (32.5) | 262 (23.8) | 1,367 (33.7) | 50 (33.6) | 4,725 (33.5) |
| College 4 years or more or advanced degree | 771 (35.7) | 710 (38.3) | 1,163 (36.9) | 1,139 (43.9) | 1,061 (39.0) | 56 (47.9) | 385 (35.0) | 1,456 (35.9) | 68 (45.6) | 5,384 (38.2) |
| Health insurance, n (%) | 2,039 (94.4) | 1,769 (95.4) | 2,976 (94.5) | 2,478 (95.4) | 2,554 (93.9) | 115 (98.3) | 1,021 (92.8) | 3,835 (94.6) | 142 (95.3) | 13,313 (94.4) |
| Employed for wages or self-employed, n (%) | 492 (22.8) | 405 (21.8) | 1,103 (56.9) | 1,107 (42.6) | 1,045 (38.4) | 41 (35.0) | 372 (33.8) | 1,429 (35.3) | 52 (34.9) | 5,246 (37.2) |
| Annual household income, n (%) | ||||||||||
| Less 10 k | 190 (8.8) | 176 (9.5) | 439 (13.9) | 344 (13.3) | 421 (15.5) | 29 (24.8) | 158 (14.4) | 578 (14.3) | 23 (15.4) | 2,051 (14.6) |
| 10-25 k | 404 (18.7) | 330 (17.8) | 561 (17.8) | 424 (16.3) | 504 (18.5) | 26 (22.2) | 237 (21.6) | 700 (17.3) | 34 (22.8) | 2,525 (17.9) |
| 25-35 k | 240 (11.1) | 187 (10.1) | 334 (10.6) | 280 (10.8) | 268 (9.9) | ≤ 20 | 98 (8.9) | 430 (10.6) | ≤ 20 | 1,436 (10.2) |
| 35-50 k | 247 (11.4) | 226 (12.2) | 337 (10.7) | 258 (9.9) | 291 (10.7) | ≤ 20 | 116 (10.6) | 417 (10.3) | ≤ 20 | 1,454 (10.3) |
| 50-75 k | 277 (12.8) | 231 (12.5) | 383 (12.2) | 338 (13.0) | 321 (11.8) | ≤ 20 | 140 (12.7) | 529 (13.1) | ≤ 20 | 1,760 (12.5) |
| 75-100 k | 172 (8.0) | 157 (8.5) | 279 (8.9) | 235 (9.1) | 233 (8.6) | ≤ 20 | 88 (8.0) | 355 (8.8) | ≤ 20 | 1,238 (8.8) |
| 100-150 k | 158 (7.3) | 157 (8.5) | 257 (8.2) | 236 (9.1) | 195 (7.2) | 0 (0.0) | 69 (6.3) | 296 (7.3) | ≤ 20 | 1,096 (7.8) |
| 150-200 k | 40 (1.9) | 37 (2.0) | 84 (2.7) | 84 (3.2) | 79 (2.9) | ≤ 20 | 25 (2.3) | 111 (2.7) | ≤ 20 | 393 (2.8) |
| More 200 k | 54 (2.5) | 41 (2.2) | 77 (2.4) | 96 (3.7) | 75 (2.8) | ≤ 20 | 27 (2.5) | 105 (2.6) | ≤ 20 | 395 (2.8) |
Abbreviations: SD standard deviation, SSRIs selective serotonin reuptake inhibitors
Results were reported in compliance with the AoU Data and Statistics Dissemination Policy prohibiting the display of participant counts ranging 1 to 20